Arbutus Biopharma (ABUS) Cash from Financing Activities (2013 - 2026)

Arbutus Biopharma has disclosed Cash from Financing Activities across 14 years of filings, most recently posting $11.6 million for Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $11.6 million, up 317.35% year-over-year; the trailing twelve-month figure through Mar 2026 was $14.6 million (down 52.04% YoY), and the FY2025 annual result was $5.7 million, down 89.0% from the prior year.
• Cash from Financing Activities came in at $11.6 million for Q1 2026 at Arbutus Biopharma, up from $1.6 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $24.4 million in Q1 2024 to a low of $113000.0 in Q2 2022.
• The 5-year median for Cash from Financing Activities is $3.8 million (2023), against an average of $7.8 million.
• Across the five-year window, Cash from Financing Activities jumped 4096.46% in 2023 and slumped 98.14% in 2025, its largest moves.
• Arbutus Biopharma's Cash from Financing Activities stood at $11.1 million in 2022, then sank by 65.65% to $3.8 million in 2023, then plunged by 62.67% to $1.4 million in 2024, then advanced by 15.41% to $1.6 million in 2025, then soared by 608.48% to $11.6 million in 2026.
• The last three Cash from Financing Activities figures came in at $11.6 million (Q1 2026), $1.6 million (Q4 2025), and $844000.0 (Q3 2025), per Business Quant data.